Shanghai Henlius Biotech, Inc. engages in the production and sale of monoclonal antibody (mAb) drugs and the provision of related consultation and technical services, and the transfer of its own technology. The company is headquartered in Shanghai, Shanghai and currently employs 3,537 full-time employees. The company went IPO on 2019-09-25. The Company’s main products include HANQUYOU (trastuzumab for injection), HANNAIJIA (neratinib maleate), HANSIZHUANG (serplulimab injection), HANLIKANG (rituximab injection), HANDAYUAN (adalimumab injection), HANBEITAI (bevacizumab injection) and others. The Company’s products are mainly used in the treatment of adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, metastatic non-squamous non-small cell lung cancer, polyarticular juvenile idiopathic arthritis and others. The firm mainly operates its businesses in the domestic and overseas markets.
02696.HK stock price ended at $60.9 on 水曜日, after dropping 3.49%
On the latest trading day Jan 21, 2026, the stock price of 02696.HK fell by 3.49%, dropping from $63.10 to $60.90. During the session, the stock saw a volatility of 4.99%, with prices oscillating between a daily low of $60.10 and a high of $63.10. On the latest trading day, the trading volume for 02696.HK decreased by 315.9K shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 312.1K shares were traded, with a market value of approximately $9.9B.